Seasonal influenza vaccination and technologies
- PMID: 24691877
- DOI: 10.1002/jcph.299
Seasonal influenza vaccination and technologies
Abstract
Seasonal influenza is a serious respiratory illness that causes annual worldwide epidemics resulting in significant morbidity and mortality. Influenza pandemics occur about every 40 yrs, and may carry a greater burden of illness and death than seasonal influenza. Both seasonal influenza and pandemic influenza have profound economic consequences. The combination of current vaccine efficacy and viral antigenic drifts and shifts necessitates annual vaccination. New manufacturing technologies in influenza vaccine development employ cell culture and recombinant techniques. Both allow more rapid vaccine creation and production. In the past 5 years, brisk, highly creative activity in influenza vaccine research and development has begun. New vaccine technologies and vaccination strategies are addressing the need for viable alternatives to egg production methods and improved efficacy. At present, stubborn problems of sub-optimal efficacy and the need for annual immunization persist. There is an obvious need for more efficacious vaccines and improved vaccination strategies to make immunization easier for providers and patients. Mitigating this serious annual health threat remains an important public health priority.
Keywords: Human/immunology/*prevention & control; Influenza; Influenza A; Influenza B; Influenza vaccines.
© 2014, The American College of Clinical Pharmacology.
Similar articles
-
Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Biotechnol J. 2015 May;10(5):690-701. doi: 10.1002/biot.201400393. Epub 2015 Mar 2. Biotechnol J. 2015. PMID: 25728134 Review.
-
Recombinant vaccines for influenza virus.Curr Opin Investig Drugs. 2008 Aug;9(8):836-45. Curr Opin Investig Drugs. 2008. PMID: 18666031 Review.
-
Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.Vaccine. 2016 Oct 26;34(45):5436-5441. doi: 10.1016/j.vaccine.2016.08.018. Epub 2016 Sep 1. Vaccine. 2016. PMID: 27593158 Free PMC article.
-
Vaccination against influenza: role and limitations in pandemic intervention plans.Expert Rev Vaccines. 2012 Aug;11(8):1009-19. doi: 10.1586/erv.12.63. Expert Rev Vaccines. 2012. PMID: 23002981 Review.
-
Prospects for controlling future pandemics of influenza.Virus Res. 2011 Dec;162(1-2):39-46. doi: 10.1016/j.virusres.2011.09.024. Epub 2011 Sep 22. Virus Res. 2011. PMID: 21963676 Review.
Cited by
-
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.Adv Ther. 2025 May;42(5):2040-2077. doi: 10.1007/s12325-025-03117-7. Epub 2025 Mar 10. Adv Ther. 2025. PMID: 40063213 Free PMC article.
-
Multivalent COBRA Hemagglutinin and Neuraminidase Influenza Vaccines Adjuvanted with TLR9 Agonist CpG 1018.Vaccines (Basel). 2025 Jun 20;13(7):662. doi: 10.3390/vaccines13070662. Vaccines (Basel). 2025. PMID: 40733639 Free PMC article.
-
Commercial influenza vaccines vary in HA-complex structure and in induction of cross-reactive HA antibodies.Nat Commun. 2023 Mar 30;14(1):1763. doi: 10.1038/s41467-023-37162-z. Nat Commun. 2023. PMID: 36997521 Free PMC article.
-
Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.PLoS One. 2017 Jan 4;12(1):e0169501. doi: 10.1371/journal.pone.0169501. eCollection 2017. PLoS One. 2017. PMID: 28052136 Free PMC article.
-
Structure-guided assembly of an influenza spike nanobicelle vaccine provides pan H1 intranasal protection.bioRxiv [Preprint]. 2024 Sep 16:2024.09.16.613335. doi: 10.1101/2024.09.16.613335. bioRxiv. 2024. PMID: 39372767 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous